Biotech Stock Roundup: Gilead Gets FDA Nod For HCV Drug, Regulus Hit By Clinical Hold

 | Jun 29, 2016 02:23AM ET

Gilead (NASDAQ:GILD) once again showed its expertise in the hepatitis C virus (HCV) segment by gaining FDA approval for yet another drug, Epclusa. However, another company, Regulus (NASDAQ:RGLS) suffered a setback related to its experimental HCV treatment.

Recap of the Week’s Most Important Stories

1. Gilead got some good news for both its key franchises – HIV and HCV. The company gained European approval for its HIV treatment, Odefsey, the second single tablet regimen containing the Descovy backbone and the third product in the company’s new TAF portfolio to gain approval in Europe (Read more: MEDICAL-BIOMED/GENETICS Industry Price Index

Among major biotech stocks, Gilead gained 0.6% over the last five trading days while Alexion (NASDAQ:ALXN) was impacted by the Brexit sell-off with shares declining 7.4%. Over the last six months, Alexion lost 39.2%.